Brenetafusp  (Synonyms: IMC-F106C)

Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3⁺ T cells to kill PRAME⁺ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer^[1].

scFv-TR-Alpha_Beta-2

Human

CD3E & PRAME

Brenetafusp (10^-13-10^-8 M) potently activates T cells in a dose-dependent manner against HLA-A*02:01+ PRAME+ MEL624, MEWO, SKMEL5, and C32 melanoma cell lines, with EC₅₀ values ranging from 12.4 to 98.0 pM^[1].
Brenetafusp (10^-14-10^-9 M) potently mediates T cell-directed cytotoxicity against HLA-A*02:01+ PRAME+ MEL624, MEWO, and C32 melanoma cell lines, with EC₅₀ values ranging from 2.99 to 20.4 pM^[1].
Brenetafusp (10^-13-10^-8 M) potently activates T cells in a dose-dependent manner against HLA-A*02:01+ PRAME+ NCI-H1755 and NCI-H1703 NSCLC cell lines, with EC₅₀ values of 17.9 and 76.9 pM, respectively^[1].
Brenetafusp (10^-14-10^-9 M) potently mediates T cell-directed cytotoxicity against HLA-A*02:01+ PRAME+ NCI-H1755 and NCI-H1703 NSCLC cell lines, with EC₅₀ values of 1.3 and 4.4 pM, respectively^[1].
Brenetafusp (10^-13-10^-8 M) potently activates T cells in a dose-dependent manner against HLA-A*02:01+ PRAME+ OV56 and COV318 ovarian cancer cell lines, with EC₅₀ values of 2.4 and 17.4 pM, respectively^[1].
Brenetafusp (10^-14-10^-9 M) potently mediates T cell-directed cytotoxicity against HLA-A*02:01+ PRAME+ OV56 and COV318 ovarian cancer cell lines, with EC₅₀ values of 1.6 and 10.5 pM, respectively^[1].
Brenetafusp (10-1000 pM) effectively redirects T cells to induce dose-dependent apoptosis in HLA-A*02:01⁺ PRAME⁺ patient-derived tumor organoids^[1].
Brenetafusp (10^-13-10^-8 M) mediated T cell activation is dependent on PRAME expression in MEL624 melanoma cells, with robust activity in parental cells, reduced activity in PRAME KO cells, and dose-dependent restored activity in PRAME-rescued KO cells^[1].
Brenetafusp (10-100 pM; 80 hours) redirects PD-1⁺ exhausted TILs to kill PD-L1⁺ MEL624 melanoma cells, with impaired activity that is fully rescued by anti-PD-1 antibody^[1].
Brenetafusp (up to 10 nM for bronchial epithelial cells; down to 1 nM for melanocytes) shows minimal reactivity against primary normal human bronchial epithelial cells and melanocytes, demonstrating specificity for PRAME⁺ tumor cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

916  [NCBI] & 23532  [NCBI]

P07766 & P78395

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

76.98 kDa

2736407-54-6

Liquid

Colorless to light yellow

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  scFv-TR-Alpha_Beta-2
• 
  Flow cytometric analysis of 1X10⁶ Jurkat cells with Brenetafusp (HY-P990717, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/50 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Flow cytometric analysis of 1X10⁶ THP-1 cells with Brenetafusp (HY-P990717, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/50 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Ribeiro AR, et al. High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME. Immunother Adv. 2024;4(1):ltae008. Published 2024 Nov 2.  [Content Brief]